124 related articles for article (PubMed ID: 31679807)
1. Are targeted prostate biopsies ready to replace systematic prostate biopsies?
Celma A; López R; Roche S; Planas J; Regis L; Placer J; Borque A; Esteban LM; de Torres I; Morote J
Actas Urol Esp (Engl Ed); 2019 Dec; 43(10):573-578. PubMed ID: 31679807
[TBL] [Abstract][Full Text] [Related]
2. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
3. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.
Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS
Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550
[TBL] [Abstract][Full Text] [Related]
4. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
5. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
Arsov C; Rabenalt R; Blondin D; Quentin M; Hiester A; Godehardt E; Gabbert HE; Becker N; Antoch G; Albers P; Schimmöller L
Eur Urol; 2015 Oct; 68(4):713-20. PubMed ID: 26116294
[TBL] [Abstract][Full Text] [Related]
6. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
[TBL] [Abstract][Full Text] [Related]
8. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Schouten MG; van der Leest M; Pokorny M; Hoogenboom M; Barentsz JO; Thompson LC; Fütterer JJ
Eur Urol; 2017 Jun; 71(6):896-903. PubMed ID: 28063613
[TBL] [Abstract][Full Text] [Related]
9. How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
Song G; Ruan M; Wang H; Fan Y; He Q; Lin Z; Li X; Li P; Wang X; He Z; Zhou L
J Urol; 2020 Dec; 204(6):1202-1208. PubMed ID: 32716686
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
11. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
12. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
13. A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.
Boesen L; Thomsen FB; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thomsen HS; Jakobsen H
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):609-616. PubMed ID: 30988407
[TBL] [Abstract][Full Text] [Related]
14. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
[TBL] [Abstract][Full Text] [Related]
15. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy.
Kenigsberg AP; Renson A; Rosenkrantz AB; Huang R; Wysock JS; Taneja SS; Bjurlin MA
Eur Urol Oncol; 2018 Oct; 1(5):418-425. PubMed ID: 31158081
[TBL] [Abstract][Full Text] [Related]
17. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
18. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.
Ukimura O; Marien A; Palmer S; Villers A; Aron M; de Castro Abreu AL; Leslie S; Shoji S; Matsugasumi T; Gross M; Dasgupta P; Gill IS
World J Urol; 2015 Nov; 33(11):1669-76. PubMed ID: 25656687
[TBL] [Abstract][Full Text] [Related]
19. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men.
Yarlagadda VK; Lai WS; Gordetsky JB; Porter KK; Nix JW; Thomas JV; Rais-Bahrami S
Diagn Interv Radiol; 2018; 24(3):115-120. PubMed ID: 29770762
[TBL] [Abstract][Full Text] [Related]
20. [Focusing on MRI-suspected lesions in targeted transrectal prostate biopsy guided by MRI-TRUS fusion imaging for the diagnosis of prostate cancer].
Qu HW; Liu H; Cui ZL; Jin XB; Zhao Y; Wang MW; Song W; Zhang XJ
Zhonghua Nan Ke Xue; 2016 Sep; 22(9):782-786. PubMed ID: 29071873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
